The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Prostate cancer as a model for tumour immunotherapy
Open accessAbstract
Advances in basic immunology have led to an improved understanding of the interactions between the immune system and tumours, generating renewed interest in approaches that aim to treat cancer immunologically. As clinical and preclinical studies of tumour immunotherapy illustrate several immunological principles, a review of these data is broadly instructive and is particularly timely now that several agents are beginning to show evidence of efficacy. This is especially relevant in the case of prostate cancer, as recent approval of sipuleucel-T by the US Food and Drug Administration marks the first antigen-specific immunotherapy approved for cancer treatment. Although this Review focuses on immunotherapy for prostate cancer, the principles discussed are applicable to many tumour types, and the approaches discussed are highlighted in that context.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“Although the cytotoxic effects of radiation therapy are well appreciated, recent data support the notion that irradiation of cancer cells can prime an antitumour immune respons”
BackgroundCancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Self-citationTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Paradoxical roles of the immune system during cancer development
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1782 · Cited by 2,256
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Inflammation in prostate carcinogenesis
De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., & Nelson, W. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2090 · Cited by 1,621
Self-citationASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Prostate cancer in a transgenic mouse.
Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., & Rosen, J. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3439 · Cited by 1,294
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., Manson, K., Panicali, D. L., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 982
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966
Higano, C. S., Schellhammer, P. F., Small, E. J., Burch, P. A., Nemunaitis, J., Yuh, L., Provost, N., & Frohlich, M. W. (2009) · Cancer · doi:10.1002/cncr.24429 · Cited by 810
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 688
Self-citationPrognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., & Vogelzang, N. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.100 · Cited by 674
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer
Ammirante, M., Luo, J.-L., Grivennikov, S., Nedospasov, S., & Karin, M. (2010) · Nature · doi:10.1038/nature08782 · Cited by 639
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.145 · Cited by 600
A history of prostate cancer treatment.
Denmeade, S. R., & Isaacs, J. T. (2002) · Nature reviews. Cancer · doi:10.1038/nrc801 · Cited by 591
Gilboa, E. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31205 · Cited by 588
The anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
Shi, Y., Liu, C. H., Roberts, A. I., Das, J., Xu, G., Ren, G., Zhang, Y., Zhang, L., Yuan, Z. R., Tan, H. S. W., et al. (2006) · Cell Research · doi:10.1038/sj.cr.7310017 · Cited by 547
Grosso, J. F., Kelleher, C. C., Harris, T. J., Maris, C. H., Hipkiss, E. L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 547
Self-citationIwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
Prostate Specific Antigen Best Practice Statement: 2009 Update
Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor, A. O., Stanford, J. L., Zietman, A., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.093 · Cited by 517
Bander, N. H., Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., & Goldsmith, S. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.160 · Cited by 509
Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade
Sutherland, J. S., Goldberg, G. L., Hammett, M. V., Uldrich, A. P., Berzins, S. P., Heng, T. S., Blazar, B. R., Millar, J. L., Malin, M. A., Chidgey, A. P., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2741 · Cited by 486
Chakraborty, M., Abrams, S. I., Camphausen, K., Liu, K., Scott, T., Coleman, C. N., & Hodge, J. W. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.6338 · Cited by 467
Machiels, J.-P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., & Jaffee, E. M. (2001) · PubMed · Cited by 453
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Willimsky, G., & Blankenstein, T. (2005) · Nature · doi:10.1038/nature03954 · Cited by 445
Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin
Luo, J.-L., Tan, W., Ricono, J. M., Korchynskyi, O., Zhang, M., Gonias, S. L., Cheresh, D. A., & Karin, M. (2007) · Nature · doi:10.1038/nature05656 · Cited by 436
Chakraborty, M., Abrams, S. I., Coleman, C. N., Camphausen, K., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0073 · Cited by 435
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing
Sfanos, K. S., Bruno, T. C., Maris, C. H., Xu, L., Thoburn, C. J., DeMarzo, A. M., Meeker, A. K., Isaacs, W. B., & Drake, C. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5164 · Cited by 427
Self-citationCD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients
Miller, A. M., Lundberg, K., Özenci, V., Banham, A. H., Hellström, M., Egevad, L., & Pisa, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7398 · Cited by 421
DNA vaccines: precision tools for activating effective immunity against cancer
Rice, J., Ottensmeier, C. H., & Stevenson, F. K. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2326 · Cited by 415
Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. J., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., et al. (1998) · The Journal of Urology · doi:10.1097/00005392-199802001-00032 · Cited by 410
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
Bronte, V., Kasic, T., Gri, G., Gallana, K., Borsellino, G., Marigo, I., Battistini, L., Iafrate, M., Prayer-Galetti, T., Pagano, F., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042028 · Cited by 396
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
Mercader, M., Bodner, B. K., Moser, M. T., Kwon, P. S., Park, E. S. Y., Manecke, R. G., Ellis, T. M., Wojcik, E. M., Yang, D., Flanigan, R. C., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251140998 · Cited by 393
ADLER, H. L., McCURDY, M. A., KATTAN, M. W., TIMME, T. L., SCARDINO, P. T., & THOMPSON, T. C. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)62092-5 · Cited by 386
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2005) · Journal of Urology · doi:10.1016/s0022-5347(18)34858-4 · Cited by 386
Gulley, J. L., Arlen, P. M., Bastian, A., Morin, S., Marte, J., Beetham, P., Tsang, K.-Y., Yokokawa, J., Hodge, J. W., Ménard, C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2062 · Cited by 370
The multiethnic cohort study: exploring genes, lifestyle and cancer risk
Kolonel, L. N., Altshuler, D., & Henderson, B. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1389 · Cited by 367
Zippelius, A., Batard, P., Rubio-Godoy, V., Bioley, G., Liénard, D., Lejeune, F., Rimoldi, D., Guillaume, P., Meidenbauer, N., Mackensen, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3066 · Cited by 361
Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer
Kiniwa, Y., Miyahara, Y., Wang, H. Y., Peng, W., Peng, G., Wheeler, T. M., Thompson, T. C., Old, L. J., & Wang, R.-F. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0842 · Cited by 352
Thomas, A. M., Santarsiero, L. M., Lutz, E. R., Armstrong, T. D., Chen, Y.-C., Huang, L.-Q., Laheru, D. A., Goggins, M., Hruban, R. H., & Jaffee, E. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031435 · Cited by 347
Fong, L., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8954 · Cited by 323
Walsh, P. C., DeWeese, T. L., & Eisenberger, M. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp0706784 · Cited by 321
Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R. M., & Ohashi, P. S. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.645 · Cited by 309
Keilholz, U., Weber, J., Finke, J. H., Gabrilovich, D. I., Kast, W. M., Disis, M. L., Kirkwood, J. M., Scheibenbogen, C., Schlom, J., Maino, V. C., et al. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200203000-00001 · Cited by 298
A triad of costimulatory molecules synergize to amplify T-cell activation.
Hodge, J. W., Sabzevari, H., Yafal, A. G., Gritz, L. R., Lorenz, M. G., & Schlom, J. (1999) · PubMed · Cited by 297
Gulley, J. L., Arlen, P. M., Madan, R. A., Tsang, K.-Y., Pazdur, M. P., Skarupa, L., Jones, J. L., Poole, D. J., Higgins, J. P., Hodge, J. W., et al. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0782-8 · Cited by 297
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
Drake, C. G., Doody, A. D. H., Mihalyo, M. A., Huang, C.-T., Kelleher, E., Ravi, S., Hipkiss, E. L., Flies, D. B., Kennedy, E. P., Long, M., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.027 · Cited by 289
Self-citationGannon, P. O., Poisson, A. O., Delvoye, N., Lapointe, R., Mes-Masson, A.-M., & Saad, F. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.004 · Cited by 261
Fong, L., Kwek, S. S., O'Brien, S., Kavanagh, B., McNeel, D. G., Weinberg, V., Lin, A. M., Rosenberg, J., Ryan, C. J., Rini, B. I., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3529 · Cited by 246
Emens, L. A., Asquith, J. M., Leatherman, J. M., Kobrin, B. J., Petrik, S., Laiko, M., Levi, J., Daphtary, M. M., Biedrzycki, B., Wolff, A. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3494 · Cited by 236
Small, E. J., Sacks, N., Nemunaitis, J., Urba, W. J., Dula, E., Centeno, A. S., Nelson, W. G., Ando, D., Howard, C., Borellini, F., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2937 · Cited by 235
Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+
Sfanos, K. S., Bruno, T. C., Meeker, A. K., De Marzo, A. M., Isaacs, W. B., & Drake, C. G. (2009) · The Prostate · doi:10.1002/pros.21020 · Cited by 233
Self-citationClinical states in prostate cancer: toward a dynamic model of disease progression
Scher, H. I., & Heller, G. (2000) · Urology · doi:10.1016/s0090-4295(99)00471-9 · Cited by 232
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Weber, J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0653-8 · Cited by 224
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
Madan, R. A., Arlen, P. M., Mohebtash, M., Hodge, J. W., & Gulley, J. L. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902997928 · Cited by 219
Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Sheehan, C. E., Vallabhajosula, S., Goldsmith, S. J., Ross, J. S., & Bander, N. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8097 · Cited by 217
Higano, C. S., Corman, J. M., Smith, D. C., Centeno, A. S., Steidle, C. P., Gittleman, M., Simons, J. W., Sacks, N., Aimi, J., & Small, E. J. (2008) · Cancer · doi:10.1002/cncr.23669 · Cited by 210
Sanda, M. G., Smith, D. C., Charles, L. G., Hwang, C., Pienta, K. J., Schlom, J., Milenic, D., Panicali, D., & Montie, J. E. (1999) · Urology · doi:10.1016/s0090-4295(98)00539-1 · Cited by 201
Harrington, L. E., Most, R. V. D., Whitton, J. L., & Ahmed, R. (2002) · Journal of Virology · doi:10.1128/jvi.76.7.3329-3337.2002 · Cited by 201
Nemunaitis, J., Jahan, T., Ross, H., Sterman, D., Richards, D., Fox, B., Jablons, D., Aimi, J., Lin, A., & Hege, K. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700922 · Cited by 180
Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer
Nesslinger, N. J., Sahota, R. A., Stone, B., Johnson, K., Chima, N., King, C., Rasmussen, D., Bishop, D., Rennie, P. S., Gleave, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1772 · Cited by 168
Simons, J. W., & Sacks, N. (2006) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2005.08.021 · Cited by 161
Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
Wada, S., Yoshimura, K., Hipkiss, E. L., Harris, T. J., Yen, H., Goldberg, M. V., Grosso, J. F., Getnet, D., Marzo, A. M. D., Netto, G. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4102 · Cited by 152
Self-citationMadan, R. A., Gulley, J. L., Schlom, J., Steinberg, S. M., Liewehr, D. J., Dahut, W. L., & Arlen, P. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5048 · Cited by 150
Clinical Use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen
Nanus, D. M., Milowsky, M. I., Kostakoğlu, L., et al. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000095151.97404.7c · Cited by 145
Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer
Tagawa, S. T., Beltran, H., Vallabhajosula, S., Goldsmith, S. J., Osborne, J. R., Matulich, D., Petrillo, K., Parmar, S., Nanus, D. M., & Bander, N. H. (2010) · Cancer · doi:10.1002/cncr.24795 · Cited by 144
Aragon‐Ching, J. B. (2007) · Frontiers in bioscience · doi:10.2741/2441 · Cited by 137
Fong, L. H., Ruegg, C. L., Brockstedt, D. G., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.7.3113 · Cited by 128
Arlen, P. M., Gulley, J. L., Todd, N., Lieberman, R., Steinberg, S. M., MORIN, S., Bastian, A., Marté, J. L., Tsang, K.-Y., Beetham, P. K., et al. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000165159.33772.5b · Cited by 108
Morse, M. D., & McNeel, D. G. (2010) · Human Immunology · doi:10.1016/j.humimm.2010.02.007 · Cited by 105
Wolpoe, M. E., Lutz, E. R., Ercolini, A. M., Murata, S., Ivie, S. E., Garrett, E. S., Emens, L. A., Jaffee, E. M., & Reilly, R. T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.2161 · Cited by 104
Williams, S. A., Singh, P., Isaacs, J. T., & Denmeade, S. R. (2006) · The Prostate · doi:10.1002/pros.20531 · Cited by 102
Koh, Y. T., Gray, A., Higgins, S. A., Hubby, B., & Kast, W. M. (2009) · The Prostate · doi:10.1002/pros.20906 · Cited by 102
Borrello, I., Levitsky, H. I., Stock, W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205278 · Cited by 98
Smith, B. D., Kasamon, Y. L., Kowalski, J., Gocke, C. D., Murphy, K. M., Miller, C. B., Garrett-Mayer, E. S., Tsai, H., Lu, Q., Chia, C. Y., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2046 · Cited by 95
Anderson, M. J. M., Shafer-Weaver, K., Greenberg, N. M., & Hurwitz, A. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1268 · Cited by 92
Prostate Specific Antigen Recurrence After Definitive Therapy
Freedland, S. J., & Moul, J. W. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.01.137 · Cited by 91
Radiotherapy augments the immune response to prostate cancer in a time‐dependent manner
Harris, T. J., Hipkiss, E. L., Borzillary, S., Wada, S., Grosso, J. F., Yen, H., Getnet, D., Bruno, T. C., Goldberg, M. V., Pardoll, D. M., et al. (2008) · The Prostate · doi:10.1002/pros.20794 · Cited by 89
Self-citationShafer-Weaver, K., Anderson, M. J. M., Stagliano, K. E., Malyguine, A. M., Greenberg, N. M., & Hurwitz, A. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900848 · Cited by 80
Degl'Innocenti, E., Grioni, M., Boni, A., Camporeale, A., Bertilaccio, M. T. S., Freschi, M., Monno, A., Arcelloni, C., Greenberg, N. M., & Bellone, M. (2004) · European Journal of Immunology · doi:10.1002/eji.200425531 · Cited by 78
Terasawa, H., Tsang, K.-Y., Gulley, J. L., Arlen, P. M., & Schlom, J. (2002) · PubMed · Cited by 77
Lyman, M. A., Aung, S., Biggs, J., & Sherman, L. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6558 · Cited by 76
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells
Tsen, S., Paik, A. H., Hung, C., & Wu, T.-C. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.2.227 · Cited by 70
Enhancing efficacy of therapeutic vaccinations by combination with other modalities
Gulley, J. L., Madan, R. A., & Arlen, P. M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.091 · Cited by 68
Rapid tolerization of virus-activated tumor-specific CD8 + T cells in prostate tumors of TRAMP mice
Bai, A., Higham, E. M., Eisen, H. N., Wittrup, K. D., & Chen, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805599105 · Cited by 67
Beer, T. M., Slovin, S. F., Higano, C. S., Tejwani, S., Dorff, T. B., Stankevich, E., & Lowy, I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5004 · Cited by 60
Assessing oncologic benefit in clinical trials of immunotherapy agents
Hales, R. K., Banchereau, J., Ribas, A., Tarhini, A. A., Weber, J. S., Fox, B. A., & Drake, C. G. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq048 · Cited by 55
Self-citationPhase II Oncology Trials: Let's Be Positive
Ratain, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1046 · Cited by 52
Current status of immunological therapies for prostate cancer
Antonarakis, E. S., & Drake, C. G. (2010) · Current Opinion in Urology · doi:10.1097/mou.0b013e3283381793 · Cited by 51
Self-citationCumulative effect of five genetic variants on prostate cancer risk in multiple study populations
Sun, J., Chang, B., Isaacs, S. D., Wiley, K. E., Wiklund, F. E., Stattin, P. E., Duggan, D. J., Carpten, J. D., Trock, B. J., Partin, A. W., et al. (2008) · The Prostate · doi:10.1002/pros.20793 · Cited by 51
Arlen, P. M., Kaufman, H. L., & DiPaola, R. S. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.006 · Cited by 40
Immunotherapy for prostate cancer
Fong, L. H., & Small, E. J. (2006) · Current Urology Reports · doi:10.1007/s11934-006-0027-8 · Cited by 40
Getnet, D., Maris, C. H., Hipkiss, E. L., Grosso, J. F., Harris, T. J., Yen, H., Bruno, T. C., Wada, S., Adler, A. J., Georgantas, R. W., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803400 · Cited by 37
Self-citationLees, J. R., Charbonneau, B., Hayball, J. D., Diener, K. R., Brown, M. P., Matusik, R. J., Cohen, M. B., & Ratliff, T. L. (2005) · The Prostate · doi:10.1002/pros.20307 · Cited by 31
Prell, R. A., Gearin, L., Simmons, A. D., VanRoey, M. J., & Jooss, K. U. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0116-4 · Cited by 31
Fox, S. B., Launchbury, R., Bates, G. J., Cheng, H., Shaida, N., Malone, P. R., Harris, A. L., & Banham, A. H. (2007) · The Prostate · doi:10.1002/pros.20538 · Cited by 29
Mihalyo, M. A., Hagymasi, A. T., Slaiby, A. M., Nevius, E., & Adler, A. J. (2007) · The Prostate · doi:10.1002/pros.20549 · Cited by 27
Immunotherapy for prostate cancer
Fong, L. H., & Small, E. J. (2007) · Current Oncology Reports · doi:10.1007/s11912-007-0026-z · Cited by 20
Immunotherapy for prostate cancer - recent progress in clinical trials.
Kipp, R. T., & McNeel, D. G. (2007) · PubMed · Cited by 11
Pitfalls or Promise in Prostate Cancer Immunotherapy—Which Is Winning?
Slovin, S. F. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318161bffa · Cited by 8
Moog-Lutz (1997) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0215(19970410)71:2
Cited by
Beer, T. M., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., Ganju, V., Polikoff, J., Saad, F., Humanski, P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1584 · Cited by 765
Self-citationDe Nunzio, C., Kramer, G., Marberger, M., Montironi, R., Nelson, W., Schröder, F., Sciarra, A., & Tubaro, A. (2011) · European Urology · doi:10.1016/j.eururo.2011.03.055 · Cited by 454
van den Eertwegh, A. J., Versluis, J., van den Berg, H. P., Santegoets, S. J., van Moorselaar, R. J. A., van der Sluis, T. M., Gall, H. E., Harding, T. C., Jooss, K., Lowy, I., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70007-4 · Cited by 357
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants
Hirschhorn, D., Budhu, S., Kraehenbuehl, L., Gigoux, M., Schröder, D., Chow, A., Ricca, J. M., Gasmi, B., De Henau, O., Mangarin, L. M. B., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.007 · Cited by 303
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271
Metadata
- Authors
- Drake, C. G.
- Venue
- Nature Reviews Immunology
- Published
- 2010-08
- Volume
- 10
- Issue
- 8
- Pages
- 580-593
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W1978942158
- Cited by
- 347
- References
- 130
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.